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cense.Abstract Objective: The purpose of our study was to investigate whether adding diffusion
weighted imaging to dynamic contrast-enhanced MRI could improve the diagnostic performance
of breast MRI.
Materials and methods: This retrospective study included 86 women with 93 primary and postop-
erative breast lesions detected on DCE-MRI who underwent subsequent biopsy. The diagnostic
performance was calculated for DCE-MRI alone, combined DCE-MRI and quantitative DWI,
and for quantitative DWI alone.
Results: Of the 93 lesions, 42 were benign and 51 malignant (5 DCIS, 41 IDC, 2 ILC, 3 NOS). Both
DCIS (mean ADC= 1.17 ± 0.12 · 103 mm2/s) and IDC (mean ADC, 0.98 ± 0.14) exhibited
lower mean ADC values than benign lesions (ADC value = 1.72 ± 0.36). Applying an ADC cutoff
value of 1.33 increased the speciﬁcity and PPV of DCE-breast MRI from 59.5% and 75% to 78.5%
and 83.3%, respectively. The speciﬁcity and PPV for quantitative DW-MRI alone (73.5% and
83.3%) were close to those broken out from the combined use of DCE and quantitative DW-
MRI. However, the sensitivity and NPV of DWI remains lower than that of DCE-MRI.ent of Radiodiagnosis, Ain
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312 R.H. Bassiouny et al.Conclusion: DWI shows potential for improving the diagnostic performance of breast MRI and
may reduce the number of unnecessary biopsies.
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Magnetic resonance imaging (MRI) is increasingly used as an
important tool for detecting and characterizing breast lesions
and in the preoperative assessment of breast cancer to evaluate
local/regional extent of disease and to ﬁnd additional lesions
(1,2,7). Dynamic contrast-enhanced breast MRI (DCE-MRI)
has been reported to have high sensitivity in detecting breast
cancer – reportedly as high as 88–100%, but its speciﬁcity
may be more modest – in the range of 68–96% (4–6,8). The
diagnosis in DCE-MRI is based primarily on contrast material
enhancement velocity, enhanced morphology and delayed
phase kinetics (washout, plateau, and persistent) interpreted
simultaneously. Breast carcinomas generally show a faster
and stronger signal intensity increase after a bolus injection
of Gadolinium based contrast agent than most benign lesions
and normal breast tissue. However, the speciﬁcity with which
contrast material enhancement can be used to predict malig-
nancy remains variable. The limitation of speciﬁcity of DCE-
MRI observed in several studies can be attributed to the fact
that several benign breast lesions including ﬁbroadenomas
can also show strong contrast agent enhancement such that
the signal intensity versus time curves considerably overlap
those of breast carcinomas (8,9).
In the preoperative assessment of breast carcinoma, MRI
has been shown to be superior to mammography, ultrasound
and clinical examination in determining tumor size and in
detecting multi-focal and multi-centric disease [10]. Currently,
importance is also being given to assessment of intra-ductal
spread. This is because intra-ductal spread is considered one
of the greatest risk factors for recurrence following breast con-
serving therapy (11).
Currently one of the most important indications for MRI
is the differential diagnosis between cancer recurrence and
surgical scar. In fact, breast MRI has become a common
practice in the evaluation for recurrence of breast cancer.
Both surgery and radiation can cause scarring with architec-
tural distortion of the breast, which makes assessment of lo-
cal recurrence difﬁcult by means of clinical examination,
mammography, and ultrasound. Post-treatment changes can
mimic malignancy or obscure locally recurrent breast cancer
(2,5). For these reasons, breast MRI is a useful tool in the
evaluation of such patients.
Several strategies have evolved to improve the speciﬁcity of
breast MRI. One approach has been to emphasize the mor-
phology of the lesion (7), other strategies are pharmacokinetic
analysis of the time–signal-intensity curves and the application
of a T2*weighted ﬁrst pass perfusion sequence with high tem-
poral resolution to help differentiate benign lesions such as
ﬁbroadenomas from invasive carcinoma. While passing
through the capillary network, a bolus injection of paramag-
netic contrast medium produces local ﬁeld inhomogeneity be-
tween the intra- and extravascular compartments, and this
susceptibility difference can be detected by a series of T2*-
weighted gradient-echo images (14).Diffusion-weighted MRI produces in vivo images of biolog-
ical tissues weighted with the local micro-structural character-
istics of water diffusion (14). Diffusion is the result of thermal
ﬂuctuations with a random pattern and this is often referred to
as ‘‘Brownian motion’’ (15,16). The Brownian motion of protons
in bulk water produces the signal in DWI. The apparent diffu-
sion coefﬁcient (ADC) is a calculated value used to quantify
Brownian motion; it includes Brownian motion (incoherent mo-
tion) and capillary blood circulation (coherent motion), but
coherent motion is affected less using high diffusion sensitizing
factors (b-values) (17,13). Decreased movement of molecules in
the tissue correlates with a low ADC value. The lower ADC
values of malignant tissues are primarily attributed to higher
cell density causing increased restriction of the extracellular
matrix and increased fraction of signal coming from intracellu-
lar water (1,18,20).
With new diagnostic criteria based on a combination of
DCE-MRI and DWI, we may be able to correctly diagnose
breast lesions that show equivocal ﬁndings from morphologic
and kinetic data analysis alone. Based on the same concepts,
quantitative DWI could be used as an additional tool, in asso-
ciation with the morphological and dynamic sequences, to im-
prove the evaluation of the scar area in patients with suspected
recurrence (12,5).
The purpose of this study was to verify the diagnostic accu-
racy of a combination of DCE-MRI and quantitative DWI in
the characterization of enhancing masses on breast MRI and
to improve the evaluation of the scar area in patients with sus-
pected recurrence.2. Materials and methods
2.1. Patients
During the period from September 2007 to January 2010, 91
patients were referred to the MRI unit of Ain Shams Univer-
sity School of Medicine for clinically indicated bilateral breast
MRI. The clinical indications included workup of clinically
palpable masses and evaluation of local/regional extent of dis-
ease in 56 newly diagnosed breast cancer patients and conﬁr-
mation of clinically suspicious local recurrence at the
operative scar after breast conservation-surgery in 35 cases.
All patients had undergone breast ultrasonography and the le-
sions were accordingly assigned as BIRADS category 3, 4 or 5
[31,32]. These ﬁndings included irregular or lobulated hypo-
echoic mass ± ill deﬁned or spiculated margins ±posterior
acoustic shadowing, focal area of architectural distortion,
unstable scar on successive examinations, associated mastitis,
and/or mammographically detected segmentally and/or duc-
tally arranged suspicious microcalciﬁcations. Five patients
were excluded from the study because of absence of enhancing
lesions on DCE-MRI and technical problems with the DWI se-
quences resulting from patient motion or inadequate fat sup-
pression. The study cohort therefore included 86 subjects
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including 53 primary and 33 postoperative cases.
2.2. MRI technique
The MR examinations were performed either before core-nee-
dle biopsy or at least 2 weeks after core-needle biopsy to avoid
the abnormal enhancement pattern caused by local inﬂamma-
tory reaction following biopsy. In the cases of surgical biopsy,
MRI examinations were performed no more than 2 weeks be-
fore surgery. MR imaging was performed using the Intera 1.5T
(Philips Medical Systems, The Netherlands). All patients were
placed prone with their breasts within a standard 4-channel,
receive only, breast coil covering both breasts.
Each MRI examination included (1) T1 and fast T2 non-fat
suppressed spin echo images obtained initially. The scan
parameters were as follows: For T1WSE: TR/TE: 550/8,
FOV: 360, matrix: 360 · 288, slice thickness: 3.5 mm: gap:
1.5 mm, TSE factor: 4, NSA: 1. For T2WSE: TR/TE: 4698/
120, FOV: 340, matrix: 384 · 304, slice thickness: 3 mm, gap:
1.5 mm; TSE factor: 30, NSA: 1. (2) Axial turbo short T1
inversion recovery (STIR): TR/TE/T1; 4373/70/165, ﬂip angle:
90, TSE factor: 17, matrix; 512 · 256, slice thickness: 5 mm,
gap: 1.5 mm; FOV: 360, number of slices: 20, NEX: 1–2 was
subsequently obtained. (3) Thereafter the DW MR images
were acquired using a multisection spin-echo-type single shot
EPI sequence in the axial plane. Sensitizing diffusion gradients
were applied sequentially in the x, y and z directions with b-
values of 0 and 1000 s/mm2. DW parameters were: TR/TE/
T1: 2185/72/180, FOV: 30, matrix: 128 · 128, slice thickness:
5 mm, gap: 1.5 mm, TSE: 79, two signals acquired; parallel
imaging with sensitivity encoding, with use of a parallel imag-
ing reduction factor of 2; acquisition time: 207 s. ADC maps
were generated from the diffusion-weighted images. (4) Lastly
the dynamic images with a fast ﬁeld echosequence were
sequentially obtained before and at 0, 90, 180, 270 and 360 s
after intravenous bolus injection of Gadolinium diethyleneti-
amine pentaacetic acid (total dose, 0.1 mmol/kg of body
weight) using a ﬂow rate of 2 ml/s into the antecubital vein
with a 18–20 G needle followed by a ﬂush of 20 ml of saline
solution with 10 s of time delay before beginning image acqui-
sition. The imaging parameters were as follows: TR/TE, 4.9/
2.5; ﬂip angle, 10; FOV, 400 mm; matrix, 256 · 196; thickness,
6 mm; acquisitions 1; acquisition time: 90 s. Sagittal reforma-
tions from the 3D data set of the T1W DCE images were per-
formed. Dynamic images were transferred to a workstation
(Advantage Windows 4.1). With post-processing software that
showed signal intensity changes over time the region of interest
(ROI) was selected and a dynamic curve was obtained.
2.3. Interpretation of MR ﬁndings
MRI images were analyzed by two readers each blinded with
three and half years experience in breast MR imaging who
identiﬁed suspicious areas of enhancement and categorized
them as masses and non-mass enhancement. Morphological
assessment was based on the American College of Radiology
Breast Imaging Reporting and Data System (BIRADS) lexi-
con (1,19): shape (round, oval, lobular, or irregular), margin
(smooth, irregular, or spiculated), and enhancement pattern
(homogeneous, heterogeneous, rim enhancement, dark inter-
nal septa, enhancing internal septa, or central enhancement)of the tumor mass. For non-mass enhancement, the distribu-
tion (diffuse, regional, segmental or ductal) and enhancement
pattern (homogenous, heterogeneous, stippled, reticular, den-
dritic, or clumped) were evaluated. Other ﬁndings were ana-
lyzed including: tumor size as deﬁned by the longest
dimension on DCE-MRI, time–signal-intensity curve pattern
on dynamic contrast-enhanced images, and the ADC value de-
rived from an ADC map.
2.4. Dynamic MR imaging analysis
Regions of interests (ROIs) were placed to evaluate the
enhancement pattern that was demonstrative of the highest vi-
sual enhancement. Thereafter, time–signal-intensity curves
were generated. Kinetic curve type assessment was performed
according to the BIRADS MR imaging guidelines. Time–sig-
nal-intensity curve patterns were categorized into three types
using data obtained during the last four phases of dynamic
imaging: The persistent pattern (type I), the plateau pattern
(type II), and the washout pattern (type III), in which the sig-
nal intensity decreases at least 10% after reaching the highest
point of its initial increase during the delayed phase. MRI
was considered negative in the absence of areas of suspicious
enhancement and patients were managed with follow-up alone
without biopsy.
2.4.1. Diffusion MRI analysis
In all cases the ADC value was measured in the area with path-
ological enhancement and/or in the area of prolonged scar
enhancement. The ROI was drawn freehand to include the
area of hyperintensity, encompassing as much of the abnor-
mality as possible while staying within the border of the hy-
per-intense region. Care was taken to avoid regions of high
T2 signal within a lesion, such as cyst, hematoma, necrosis
or seroma by verifying the ROI against the T2-weighted
b= 0 s/mm2 image to reduce the T2 shine-through effect.
The mean ADC of the voxels in the ROI was calculated
according to ADC= (1/b2b1) ln(S2/S1), where S1 and
S2 are the signal intensities in the regions of interest (ROI) ob-
tained with different gradient factors (b-values of 0 and 1000 s/
mm2). As a reference, we used the normal-appearing ﬁbroglan-
dular tissue that showed homogeneous signal intensity on both
the ADC map and the T1-weighted images. To place the ROI
for both time–signal-intensity curve construction and ADC
measurement in the same area, we used reference lines on an
image viewer.
The ﬁnal diagnoses were based on the histopathology re-
sults of core-needle biopsy. According to histopathology re-
sults, we categorized the breast lesions into seven groups: (1)
invasive ductal carcinoma (IDC), (2) DCIS, (3) invasive lobu-
lar carcinoma (ILC), (4) carcinoma NOS, (5) high risk lesions,
(6) benign lesions, and (7) postoperative benign changes. The
ADC values were then averaged. We compared the ADC val-
ues among the various malignant and benign lesions, the scar
tissue and the normal-appearing ﬁbroglandular tissue.
2.5. Statistics
1. Determination of cutoff level for the ADC value: To deter-
mine the ability of the ADC value to enable the differenti-
ation of malignant from benign breast lesions, the feasible
Table 1 Histopathological results.
Histolopathology Number (93)
Malignant 51
Primary malignant 37
IDC 28
DCIS 5
Invasive lobular carcinoma 2
Carcinoma NOS 2
Local recurrence at operative scar 14
IDC 13
Carcinoma NOS 1
High risk 3
Benign 39
Primary 25
Fibroadenomas 13
Fibrocystic disease 4
Focal adenosis 3
Focal ﬁbrosis 1
Inﬂammation 1
Postoperative 11
Scar 6
Liponecrosis 5
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100
1-Sp%
Sn
%
ADC NDL Best cutoff
AUC
ADC297.0
Fig. 1 ROC curve analysis showing the diagnostic performance
of ADC for discriminating cases with malignancy from those
benign.
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operating characteristic (ROC)-based positive test for all
lesions. Receiver operating characteristic analysis was used
to evaluate the effectiveness of the absolute ADC value in
the characterization of benign versus malignant breast
lesions. T-tests were used for analyzing the differences of
the mean ADC values of the IDC, ILC, DCIS, benign
lesions and normal-appearing ﬁbroglandular tissue.
2. A diagnostic validity test for the DW-MRI was performed
(Table 5) and included: the diagnostic sensitivity, the diag-
nostic speciﬁcity, the predictive value for a +ve test (PPV),
and the predictive value for a ve test (NPV).
3. Multivariate analysis: We selected covariates for multivari-
ate analysis among the variables including margin of mass,
internal mass enhancement, TIC pattern and absolute ADC
values (equal, smaller or larger than feasible ADC cutoff
value) of all mass and non-mass like lesions. All these
covariates are listed in Table 4.
4. Chi-square test was used to study the association between
each two variables as regards the categorized data.
5. Z-test for comparison between two proportions as regards
univariant categorized data.
We calculated P-values of the each predictor variables. The
probability of error at 0.05 was considered signiﬁcant, while at
0.01 and 0.001 are highly signiﬁcant.
All data were analyzed using the PASW statistical software
package (V. 18.0, IBM Corp, USA, 2010).
3. Results
3.1. Conventional MRI imaging parameters
Sixty-two enhancing lesions were detected on DCE-MRI in
53 newly presenting patients. Using a combination of mor-
phologic and dynamic ﬁndings 48 of these lesions were as-
signed a ﬁnal BIRADS assessment of 4 a, b, and c (low,
intermediate, and moderate suspicion) or 5 (highly suggestive
of malignancy) and 14 lesions were categorized as BIRADS 2
or 3 (benign or probably benign). DWI was acquired success-
fully in all these cases and core-needle or excisional biopsies
were taken after MRI. The types of contrast enhancement in-
cluded four foci (three benign and one malignant), 52 masses
(19 benign and 33 malignant), and six non-mass enhance-
ments (three benign, three DCIS). Lesion sizes, as deﬁned
by the longest dimension on DCE-MRI, ranged from 0.6
to 5.4 cm (median, 1.2 cm). The ﬁnal histopathological out-
comes were as follows: 37 (60%) malignant, three high risk,
and 22 (40%) benign lesions. The malignant lesions included:
28 IDC, two ILC, ﬁve DCIS, and two carcinoma NOS. The
high risk lesions were three atypical ductal hyperplasia
(ADH) and the 22 benign lesions included: 13 ﬁbroadeno-
mas, four ﬁbrocystic disease, three focal adenosis, one case
of focal ﬁbrosis and one case of mastitis. The results of tissue
sampling are listed in Table 1. The signiﬁcantly frequent
morphologic MR ﬁndings among the malignant lesions were
lobular or irregular shape, irregular or spiculated margin,
heterogeneous or rim enhancement, ductal, linear and seg-
mental distribution of non-mass enhancement and washout
and plateau time intensity curve (TIC) pattern (e.g. Figs. 2
and 3) whereas oval shape, smooth or gently lobulated mar-
gin, homogeneous internal enhancement, and persistent TICpattern were the signiﬁcantly frequent ﬁndings in benign le-
sions (e.g. Fig. 4). The MR ﬁndings of all lesions are summa-
rized in Table 2.
In nine of the 33 cases with suspected local recurrence no
enhancement was identiﬁed on DCE-MRI and these were con-
sidered benign. In the remaining 24 cases, 31 enhancing lesions
were identiﬁed (15 masses and 16 non-mass enhancements).
DCE-MRI was considered positive in 15 lesions based on a
Fig. 2 A 63-year-old woman with multicenteric IDC: (A) The axial T2-weighted image shows multiple rounded and lobulated iso-signal
intensity masses in left breast associated with diffuse inﬂammatory changes. (B) The dynamic-enhanced T1-weighted gradient-echo image
shows multiple, homogeneous and rim-enhancing masses in left breast. (C) The axial DWI shows multiple hyperintense masses. The ADC
values of these masses were 0.94, 0.84 and 0.1 · 10.3 mm2/s, respectively. (D) TIC shows washout and plateau patterns.
Diagnostic performance of breast MRI 315combination of morphologic and kinetic ﬁndings. According
to histopathological results, 14 of the enhancing lesions where
true recurrence in the region of scarring and all recurrences
were invasive (13 IDC and one invasive carcinoma NOS (true
+ve). See Fig. 6 for example. One DCE positive proved to be
scar tissue (false +ve). 11 lesions were negative based on com-
bination of morphological and dynamic ﬁndings and tissue
sampling revealed benign tissue in these 11 (six scar tissue
and ﬁve liponecrosis (true ve). In the remaining ﬁve lesions
DCE-MRI was inconclusive due to mismatch between mor-
phologic and kinetic ﬁndings. All these lesions were benign
on tissue sampling (four of them were scar tissue devoid ofatypical cells and one case turned out to be liponecrosis. These
ﬁve inconclusive lesions were considered false +ve by DCE-
MRI.
3.2. Diffusion-weighted and quantitative ADC imaging
characteristics
Fifty-eight of the 62 primary enhancing lesions, including both
carcinomas and benign lesions, were hyperintense on DWI
much more conspicuous at b= 0. Four lesions were isointense
to surrounding tissue and were not easily identiﬁed on DWI
(DW ve). The isointense lesions included two foci (each
Fig. 3 A 69-year-old woman with left IDC. (A) The axial T2W image shows two small homogeneous iso-signal intensity masses with
speculated margins in left breast that appeared to be interconnected by linear band of tissue. (B) The STIR sequence shows the two lesions
to be hyperintense with central hypointense zone in larger lesion. (C) In the DCE-MRI, the two lesions and the interconnecting band
elicited homogeneous enhancement with a washout TIC pattern (E). (D) Axial DW shows a high-signal intensity irregular mass with an
ADC value of 0.806 · 103 mm2/s. (F) The smaller daughter lesions was not identiﬁed on DWI.
316 R.H. Bassiouny et al.under 1 cm in size and two non-mass enhancements. These were
reported as two satellite nodules of themalignant lesions (false –
ve), one case of focal ﬁbrosis and one case of ADH (true –ve).
In all postoperative cases with positive recurrence in or near
the operative scar (14 lesions), DWI showed areas of hyperin-
tensity corresponding to the enhancing lesions. In four of the12 benign enhancing postoperative lesions (liponecrosis or
scar), DWI did not show areas of hyperintensity corresponding
to the lesions. All lesions, with inconclusive DCE-MRI ﬁnd-
ings (5) were hyperintense on DWI.
The ADC values were estimated only for the DW hyperin-
tense lesions (58 primary and 27 postoperative lesions). The
Fig. 4 A 48-year-old woman with ﬁbrocystic disease of the breasts and superadded inﬂammation. (A) The axial T2W image shows
bilateral variable sized cystic lesions. The largest in right breast shows ﬂuid–ﬂuid level and a thickened wall with smooth inner margin. A
tiny isointense nodule is noted at its vicinity. (B) The STIR, (C) the DCE-MRI and (D) axial DW image demonstrate hyperintense walls of
the cystic lesions and the tiny adjacent nodule to be also hyperintensel. The surrounding breast parenchyma shows edematous changes.
The walls and the adjacent nodules elicited ADC values of 1.7 and 1.5 · 103 mm2/s, respectively. (E and F) The MIP subtraction image
and TIC showing a TIC pattern.
Table 2 Conventional MRI ﬁndings in all lesions.
MR ﬁndings Malignant (51)
(37 1ry + 14 postop)
Benign (42)
(25 1ry = 17 postop)
Type of enhancement
Foci 1 3
Mass 33 + 14(postop) = 47 19 + 1(post) = 20
Non-mass like 3 3 + 16 (postop)
Size (mean, S.D.) (cm)
<1 3 8
1–2 30 23
>2 19 10
Shape of masses
Round 13 4
Oval 8 9
Irregular 19 1
Lobular 7 6
Margin of masses
Irregular 19 2
Smooth 11 18
Spiculated 17 0
Enhancement pattern of all lesions
Homogeneous 17 20
Heterogeneous 22 18
Rim enhancement 12 4
Size deﬁned as longest diameter on dynamic contrast-enhanced
MRI not upgraded at excision.
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IDC = 0.91 ± 0.14 · 103 mm2/s; ILC = 1.13 ± 0.08 · 103
mm2/s; and DCIS = 1.17 ± 0.12 · 103 mm2/s. The mean
ADC value for benign lesions = 1.72 ± 0.36 · 103 mm2/s
and for normal-appearing breast parenchyma the mean
ADC= 1.51 ± 0.29 · 103 mm2/s. The mean ADC value for
scar tissue = 1.6 ± 0.2 · 103 mm2/s and for liponecro-
sis = 2.1 ± 0.12 · 103 mm2/s. (Table 3).
Diagnostic validity test showed that the best cutoff value
for ADC to discriminate between malignant and benign was
1.33 · 103 mm2/s below which lesions are likely malignant
and above which likely benign (Fig. 1). Using this cutoff
ADC value, in addition to all values of DCE-MRI (including
unenhanced morphology, unenhanced signal values, enhanced
morphology and kinetics, a sensitivity = 88.2% (ability to dis-
criminate malignant) and a speciﬁcity = 78.6% (ability to dis-
criminate benign) with predictive value for a negative test
(NPV) of 84.6% (% of true negative among all negatives)
and predictive value for a positive test (PPV) of 83.3% (%
of true positive among all positives). Table 5 summarizes the
diagnostic validity of dynamic contrast MRI alone and that
after the addition of ADC cutoff values.
Despite some overlap in values between benign and malig-
nant lesions, the 51 malignant lesions exhibited signiﬁcantly
lower ADC values than the 42 benign lesions. Nine benign le-
sions (seven primary and two postoperative lesions), however,
exhibited ADC values below this cutoff level and were
therefore suspicious by quantitative DWI. An example of such
a false +ve positive DW ﬁnding is shown in (Fig. 5). Six
Fig. 5 A 67-year-old woman with atypical duct hyperplasia associated with inﬂammatory changes. (A–D) The axial T1W, T2W, DCE
and DW MR images show an iso-signal intensity mass with irregular speculated margin located superﬁcially in upper outer quadrant of
left breast associated with overlying skin thickening and surrounding high T2W signal interstitial edema. (E) The lesion elicited a benign
progressively rising curve, and ADC values of 0.851, 0.798 and 0.948 · 103 mm2/s (false +ve for recurrence).
318 R.H. Bassiouny et al.malignant lesions (ﬁve primary and one postop) elicited ADC
values above this cutoff value and therefore falsely negative by
ADC using a threshold of 1.33 · 103 mm2/s (false ve). Nev-
ertheless, if biopsy had been recommended for only those sus-
picious lesions by DCE-MRI alone that had ADC values
below 1.33 · 103 mm2/s (11), biopsy might have been avoided
for 33 of 42 benign lesions.
When diffusion weighted imaging characteristics including
qualitative (iso or hyperintense) and quantitative ADC valueswere used exclusively a sensitivity of 88.2% and a speciﬁcity of
73.5% with NPV of 80.64% and PPV of 83.3% were con-
cluded. Table 6 summarizes the diagnostic validity of diffusion
weighted imaging alone.
4. Discussion
Breast MRI is a widely accepted diagnostic approach for
detecting and evaluating breast lesions (5). For women with
Fig. 6 A 53-year-old female patient submitted 5 years previously to conservative surgery on left breast for IDC. (A) Axial T1Wi
demonstrate an isointense area of parenchymal distortion with ﬁbrous scarring and interstitial edema associated with thickening of the
overlying skin in the lower outer quadrant of left breast. (B and C) Axial DCE and STIR show evidence of hyperintense nodules located
deep at the region of the surgical scar. (E) The corresponding dynamic curve of the hyperintense nodules show a gradual initial rise
followed by an obtuse downslope of contrast washout. (D and F) the same lesions are hyperintense on DWI sequence (D) and its ADC
value of 0.72 and 0.96 · 103 mm2/s. Compared to surrounding scar tissue eliciting ADC value of 1.48 · 103 mm2/s (true +ve for
recurrence).
Diagnostic performance of breast MRI 319newly diagnosed breast cancer, the size of the primary tumor
and the presence or absence of additional previously unsus-
pected lesions are important consideration when breast conser-
vation is being contemplated. DCE-MRI exceeds all otherbreast-imaging diagnostic tools in assessing tumor size as
compared to the histologically determined tumor size. It also
provides extremely high sensitivity for identifying multiple foci
of carcinoma and accordingly it can change surgical
Table 3 The distribution of the ADC values for IDC, DCIS,
benign lesions, scar tissue, liponecrosis and normal ﬁbroglan-
dular tissue is shown.
Type of lesion Number Mean ADC (·103 mm2/s)
IDC 41 0.91 ± 0.14
DCIS 5 1.17 ± 0.12
ILC 2 1.13 ± 0.08
Benign lesions 25 1.72 ± 0.36
Scar tissue 11 1.6 ± 0.2
Liponecrosis 6 2.1 ± 0.12
Fibroglandular tissue All 1.51 ± 0.29
Table 4 Multivariate analysis.
Total % n
Margin of mass
Irregular
Benign 20 10 2
Malig 47 40.4 19
Smooth
Benign 20 85 17
Malig 47 23.4 11
Speculated
Benign 20 5 1
Malig 47 36 17
Int. Enhancm.
Hetero
Benign 42 42.9 18
Malig 51 43.1 22
Homo
Benign 42 47.6 20
Malig 51 33.3 17
Rim
Benign 42 9.5 4
Malig 51 23.5 12
TIC
Persist
Benign 42 73.8 31
Malig 51 5.9 3
Plateau
Benign 42 19 8
Malig 51 56.9 29
Washout
Benign 42 7.1 3
Malig 51 37.3 19
Category
2
Benign 42 16.7 7
Malig 51 0 0
3
Benign 42 45.2 19
ADC
P1.33
Benign 42 78.6 33
Malig 51 11.8 6
<1.33
Benign 42 21.4 9
Malig 51 88.2 45
Malign 51 0 0
320 R.H. Bassiouny et al.management of patients with operable breast cancer. It is also
currently used to evaluate response to neoadjuvant chemother-
apy for breast cancer (21,22).
The detection and quantiﬁcation of recurrent tumor in or
adjacent to the operative scar is another important clinical
question if breast conservation is being considered. Follow-
up of patients after conservative treatment frequently includes
periodic clinical examination and mammography every
6 months during the ﬁrst 2 years and every year thereafter.
The expected alterations in the treated breast include the sur-
gically caused scar formation and deformity as well as radia-
tion induced inﬂammation and ﬁbrosis. The ability of
mammography to show a cancer in the post-treatment breastZ P Sig.
1.123598 >0.05 NS
1.771101 <0.05 S
3.59915 <0.001 HS
0.019387 >0.05 NS
1.402304 >0.05 NS
1.781324 <0.05 S
6.766156 <0.001 HS
3.716187 <0.001 HS
3.410229 <0.001 HS
3.035085 <0.01 HS
6.496092 <0.001 HS
6.496092 <0.001 HS
5.381867 <0.001 HS
Table 5 Diagnostic validity of dynamic postcontrast MRI
without and with DW.
Primary
(n= 62)
Postoperative
(n= 31)
Total
(n= 93)
DCE-MRI
True +ve 37 14 51
True-ve 14 11 25
False +ve 11 6 17
False-ve 0 0 0
Sensitivity (%) 100 100 100
Speciﬁcity (%) 56 64.7 59.5
PPV (%) 79 70 75
NPV (%) 100 100 100
Eﬃcacy (%) 82.2 80 81.7
Qauntitative DW-MRI
True + ve 32 13 45
True-ve 19 14 33
False + ve 7 2 9
False –ve 5 1 6
Sensitivity (%) 86.4 92.8 88.2
Speciﬁcity (%) 73 87.5 78.5
PPV (%) 82 86.6 83.3
NPV (%) 79 93.3 84.6
Eﬃcacy (%) 80.1 90 83.8
Table 6 Diagnostic validity of diffusion weighted imaging
alone.
1ry = 58 Postoperative = 27 Total
True +ve 32 13 45
True ve 14 11 25
False +ve 7 2 9
False ve 5 1 6
Sensitivity 86.48 92.8 88.2
Speciﬁcity 66.6 84.6 73.5
PPV 82 86.666 83.333
NPP 73.68 91.666 80.64
Diagnostic performance of breast MRI 321is compromised by the increased density and surgical defor-
mity often present. In large mammographic surveillance series
in the post-treatment setting sensitivity fell to 64–71% (1).
Diagnostic problems are also encountered with ultrasonogra-
phy because of hypoechoic areas, architectural distortion,
and shadowing arising from the scar tissue (23).
In a 2006 multicenter study Schnall et al. (2) reported that
the best predictive parameters for malignancy were lesion
shape, margin, signal intensity, enhancement pattern, and ki-
netic curve type. Our results indicated that the same aspects
of DCE-MRI are the best predictors of malignancy. The ob-
served increased enhancement within primary and recurrent
tumors (compared with normal breast tissue) is a reﬂection
of the leakiness of the neo-vascularity induced by malignant
tissues. The majority of surgical scars more than 6 months
after surgery do not enhance signiﬁcantly while almost all
malignancies do enhance signiﬁcantly. Patients of our series
were examined when the MR changes related to the develop-
ment of early reactive ﬁbrosis would be considered to have re-
solved. Evaluation of the speed of enhancement in DCE-MRI
appears promising in aiding differentiation between benignand malignant lesions as well as differentiation of benign scar
from recurrent cancer.
Recently there have been several reports concerning the
usefulness of adding quantitative DWI to DCE-MRI in differ-
entiating benign and malignant breast lesions (15,17,21–24).
However, to our knowledge, there has only been a single recent
study by Rinaldi et al. (24) analyzing the value of combining
DWI and DCE-MRI for improving the diagnostic accuracy
in patients with suspected recurrence at the scar site.
Generally, in biologic tissues, ADC values are affected by
microscopic motion including both the molecular diffusion
of water (incoherent motion or Brownian motion) and the
blood microcirculation in the capillary network (coherent mo-
tion). Because of the extensive micro-vessels in malignant
breast tumor, the ADC value can be strongly affected by per-
fusion when the b-value is small (16,25,26). Several studies that
have measured the ADCs of breast lesions have shown discrep-
ancies in the ADC values using different upper b-values. For
example the mean ADCs of malignant lesions were
1.60 ± 0.36 · 103 mm2/s using b= 400 by Partridge et al.
(30); 1.12 ± 0.24 · 103 mm2/s using b= 750 by Yabuuchi
et al. (29); and 0.97 ± 0.20 · 103 mm2/s using b= 1000 by
Guo et al. (18). The reason for these discrepancies can be ex-
plained by the ADCs being calculated using linear regression
analysis and analysis of the natural log of the signal intensity
versus the different gradient factors or b-values (16,27). We ap-
plied sensitizing diffusion gradients with b-values of 0 and
1000 s/mm2, in accordance with Marini et al. (17). Because
coherent motion affects the ADC less with a high b-value such
as 1000 s/mm2 such that we could obtain diffusion effects as
measured by ADC calculation without signiﬁcant contamina-
tion from coherent motion effect.
Our results showed that the mean ADC of malignant le-
sions is 0.98 · 103 mm2/s, which correlates well with the
above-mentioned results from the literature. We compared
the ADC values of breast lesions to that of normal ﬁbroglan-
dular tissue as recommended by Park et al. (28) because ADC
values are variable depending upon the upper b-value used.
Statistically signiﬁcant differences were found between the
mean ADC values of IDC and DCIS and that of normal ﬁbro-
glandular tissue (p 6 0.05). Also the mean ADC values of
malignant lesions were statistically different from those of be-
nign tumors and scar tissue.
Rubesova et al. (13) and Sinha et al. (15) have shown prom-
ising differences between benign and malignant lesions
through a multivariate combination of ADC and DCE-MRI
features. They reported a cutoff level between benign and
malignant lesions for highest sensitivity and speciﬁcity of
1.13 and 1.1 · 103 mm2/s, respectively. In our study we as-
sumed an ADC cutoff level of 1.33 · 103 mm2/s. By applying
this cutoff level for malignant lesions, the speciﬁcity and PPV
of breast MRI was increased from 59.5% and 75% using
DCE-MRI alone to 78.6% and 83.3%, respectively, with the
addition of quantitative DWI. Applying this cutoff value could
have prevented biopsy in 33 (78.5%) of 42 benign lesions. Par-
tridge et al. (30) by applying an ADC threshold of 1.81 · 10
3 mm2/s for 100% sensitivity produced a PPV of 47% versus
37% for DCE-MRI.
Interestingly enough the diagnostic speciﬁcity broken out
when quantitative DW-MRI was used alone (73.5%) was
not signiﬁcantly lower than that calculated using a combina-
tion of DCE-MRI and DW-MRI (78.5%). Even more the
322 R.H. Bassiouny et al.PPV obtained from the exclusive use of quantitative DW-MRI
was identical to that obtained when both DCE-MRI and
quantitative DW-MRI were used together.
Several limitations arose from our study: (1) Context bias (a
large number of malignant lesions relative to benign lesions).
We usually performMRI for suspicious lesions for the purpose
of preoperative assessment of suspected breast cancer. There-
fore, because of a high pretest probability of malignancy for
our population we did not obtain a sufﬁcient number of benign
breast lesions for optimal statistical analysis. (2) A false nega-
tive rate of 6.4% emerged through the application of an ADC
cutoff value that was not existing by using the DCE-MRI cri-
teria alone. This resulted in a lower sensitivity and NPV when
adding quantitative DW-MRI to DCE-MRI or when using
quantitative DW-MRI alone (88.2% and 80.64%, respec-
tively). (3) Even though we attempted to obtain meaningful
ADC values in purely normal ﬁbroglandular tissue, in some re-
gions malignant tissue was inter mixed with normal tissue, this
was especially problematic in the cases with intra-ductal spread
of breast lesions. (4) We could not detect some satellite nod-
ules. A previous report demonstrated that nodules less than
1.0 cm in diameter are not detectable on DWI (25). (5) Some
portion of false positives seems inevitable. However, in our ser-
ies, the 22% rate of false positivity using DCE-MRI alone de-
creased to 14% if we added two DWI sequences; in fact for all
inconclusive lesions based upon DCE-MRI alone, which were
benign at biopsy, ADC was >1.33 mm2/s .5. Conclusion
We can conclude from this study that the addition of quantita-
tive DW-MRI to DCE-breast MRI would improve its diagnos-
tic speciﬁcity and would prevent a large number of unnecessary
biopsies. More important is that, despite its relatively low
sensitivity, DW-MRI can still be considered sensitive enough
with a sufﬁciently high speciﬁcity to be used as a ﬁrst round
for screeningof breast lesions perhaps in combinationwith other
non contrast sequences (e.g. DTI) preferably in other popula-
tions with lower pretest probability of malignancy.References
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